Skip to main content
SpringerLink
Log in

Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus

  • Original Article
  • Published:
Journal of Infection and Chemotherapy

Abstract

Glycopeptide antibiotics, such as vancomycin and teicoplanin, have been used worldwide to treat infection caused by methicillin-resistant Staphylococcus aureus (MRSA). Generic teicoplanin products were manufactured by many companies in 2009. We investigated the susceptibility of 147 MRSA strains to brand-name teicoplanin (TEIC-1) and seven generic products (TEIC-2 to TEIC-8). The MIC90 of generic TEIC-5 and TEIC-7 was 8 μg/ml whereas that of TEIC-1 and other generic products was 4 μg/ml. The potency equivalent of generic TEIC-5 and TEIC-7 was lower than that of TEIC-1, and TEIC content (%) per potency equivalent (200 mg) in a vial of these two generic products varied greatly compared with the other products. Although the potency equivalent of the TEIC used in this study was within the range stipulated in the Japanese Pharmacopeia, these results showed that the potency equivalent and susceptibility of two of the seven generic products differed from that of TEIC-1. The predicted AUC0–72 value of those two generic products was 84–85% in comparison with that of TEIC-1. Among generic drugs, there may be products whose antimicrobial effect is not equal to that of the brand teicoplanin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mastoraki E, Michalopoulos A, Kriaras I, Mouchtouri E, Falagas ME, Karatza D, et al. Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J Infect. 2008;56:35–9.

    Article  PubMed  Google Scholar 

  2. Rodriguez CA, Agudelo M, Catano JC, Zuluaga AF, Vesga O. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J Infect. 2009;59:277–80.

    Article  PubMed  Google Scholar 

  3. Fujimura S, Fuse K, Kikuchi T, Gomi K, Tokue Y, Watanabe A. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin. Int J Antimicrob Agents. 2008;31:391–2.

    Article  CAS  PubMed  Google Scholar 

  4. Clinical and Laboratory Standards Institute (2009) Perfomance standards for antimicrobial susceptibility testing, 19th edn. Approved standard M100-S19. CLSI, Wayne, PA.

  5. Ministry of Health, Labour and Welfare (2006) Teicoplanin. The Japanese pharmacopoeia, 15th edn. Ministry of Health, Labour and Welfare, Tokyo, Japan, pp 733–735.

  6. Nakayama K, Gemma H, Kaibara A, Niwa T. Population pharmacokinetics of teicoplanin in adult patients. Jpn J Chemother. 2006;54:1–6.

    CAS  Google Scholar 

  7. Kuti JL, Kiffer CRV, Mendes CMF, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect. 2008;14:116–23.

    Article  CAS  PubMed  Google Scholar 

  8. Schito GC, Keenan MH. Predicting the clinical efficacy of generic formulations of ceftriaxone. J Chemother. 2005;17(suppl 2):33–40.

    CAS  PubMed  Google Scholar 

  9. Martin M, Quilici S, File T, Garau J, Kureishi A, Kubin M. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother. 2007;59:977–89.

    Article  CAS  PubMed  Google Scholar 

  10. Japan Antibiotics Research Association (2000) Teicoplanin for injection. Requirements for antibiotic products of Japan. Jiho Co., Tokyo, Japan, p II-39.

Download references

Author information

Authors and Affiliations

  1. Research Division for Development of Anti-Infective Agents, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan

    Shigeru Fujimura, Katsuhiro Fuse, Hidenari Takane, Yoshihisa Nakano & Akira Watanabe

  2. Department of Respiratory Oncology and Molecular Medicine, Tohoku University School of Medicine, Sendai, Japan

    Katsuhiro Fuse, Kazunori Gomi & Toshiaki Kikuchi

Authors
  1. Shigeru Fujimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katsuhiro Fuse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hidenari Takane
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshihisa Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazunori Gomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toshiaki Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akira Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeru Fujimura.

About this article

Cite this article

Fujimura, S., Fuse, K., Takane, H. et al. Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus . J Infect Chemother 17, 30–33 (2011). https://doi.org/10.1007/s10156-010-0094-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-010-0094-0

Keywords

Search

Navigation